Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences PR...
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg PR...
Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM, Feb. 11, 2022 /PRNewswire/...
Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer PR Newswire LUND, Sweden, Feb. 1, 2022 LUND, Sweden, Feb. 1, 2022...
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR...
Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported PR Newswire LUND, Sweden, Jan. 18...
Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data PR...
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication PR Newswire LUND, Sweden and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.